A Study of Benralizumab in Patients With Eosinophilic Esophagitis (MESSINA)

AstraZeneca

Status and phase: Terminated; Phase 3

Conditions: Eosinophilic Esophagitis

Treatments: Biological: Matching placebo; Biological: Benralizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT04543409

2019-002871-32 (EudraCT Number)

D3255C00001

Details and patient eligibility

About

The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity. Upon completion of the initial 52-week treatment period, patients will be offered an additional Open Label Extension period of at least 1 year, with benralizumab treatment and ongoing study assessments.

Enrollment: 211 patients

Sex: All

Ages: 12 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients 12 to 65 years of age, inclusive, at the time of signing the informed consent or assent (if applicable) form.

• Documented previous diagnosis of EoE by endoscopy.

• Must be symptomatic at Visit 1 (screening) and Visit 2 (randomization):

  1. A patient reported an average of at least 2 days per week with an episode of dysphagia over the 4 weeks prior to Visit 1 AND
  2. An average of at least 2 days per week with an episode of dysphagia (Daily DSQ ≥2) between Visit 1 and Visit 2, and at least 2 days per week with an episode of dysphagia (Daily DSQ ≥2) in each of the 2 weeks immediately prior to randomization

• May be on background medications for EoE and related treatments during the study as long as the background medications have been stable for at least 4 weeks (8 weeks for PPI) prior to the screening and there is agreement not to change type of background medication or dosage during the run-in period and for the first 52 weeks of the study unless a change is medically indicated.

• Negative serum pregnancy test for female patients of childbearing potential at Visit1.

• Women of childbearing potential must agree to use a highly effective form of birth control (confirmed by the Investigator) from randomization throughout the study duration and within 12 weeks after last dose if IP.

Exclusion criteria

• Other GI disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, or celiac disease.

• Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation during the run-in period.

• Esophageal dilation performed within 8 weeks prior to screening and prior esophageal surgery that would impact the assessments for EoE

• Use of a feeding tube, or having a pattern of not eating solid food daily during the run-in period.

• Hypereosinophilic syndrome, defined by multiple organ involvement and persistent blood eosinophil count >1500 eos/μL.

• EGPA vasculitis.

• Eosinophilic gastritis, gastroenteritis, enteritis, or colitis documented by biopsy.

• Current malignancy, or history of malignancy with some specific exceptions.

• History of anaphylaxis to any biologic therapy or vaccine.

• Current active liver disease:

  • Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen [HBsAg] or hepatitis C antibody), or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥3 times the upper limit of normal (ULN), confirmed by repeated testing during the run-in period.

• Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent or assent (if applicable) is obtained that has not been treated with or has failed to respond to standard of care therapy.

• History of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.

• Concomitant use of immunosuppressive medication.

• Initiation or change of a food-elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to start of the run-in period.

• Currently pregnant, breastfeeding, or lactating women.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

211 participants in 2 patient groups, including a placebo group

Benralizumab

Experimental group

Description:

Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)

Treatment:

Biological: Benralizumab

Placebo

Placebo Comparator group

Description:

Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)

Treatment:

Biological: Matching placebo